Reporting from EULAR 2024 - Frederic Lavie, MD, PhD: Guselkumab Provides Robust Improvements in Pain Among Patients with PsA
The inspiration for the Cosmos phase 3b study came from discussions that investigators, including Frederic Lavie, MD, PhD, head of Global Medical Affairs Rheumatology at the Janssen Pharmaceutical Companies of Johnson & Johnson, had with providers about the challenges of treating pain in patients. Pain, he said, is often the most difficult symptom to address, even when disease activity appears controlled.
In an interview with HCPLive, Lavie explained that although the efficacy of guselkumab was previously proven in bio-naïve patients with psoriatic arthritis (PsA), there was an uncertainty about its effectiveness in patients who still experienced high pain levels after showing inadequate response to ≥ 1 tumor necrosis factor (TNF) blockers.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
